{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:38:06Z","timestamp":1775281086609,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004240","name":"Czech Academy of Sciences","doi-asserted-by":"publisher","award":["RVO:67985823"],"award-info":[{"award-number":["RVO:67985823"]}],"id":[{"id":"10.13039\/501100004240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grant Agency of the Czech Republic","doi-asserted-by":"publisher","award":["14-05696S"],"award-info":[{"award-number":["14-05696S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grant Agency of the Czech Republic","doi-asserted-by":"publisher","award":["17-16182S"],"award-info":[{"award-number":["17-16182S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2018.01.027","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T23:04:18Z","timestamp":1521155058000},"page":"129-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Role of membrane cholesterol in differential sensitivity of muscarinic receptor subtypes to persistently bound xanomeline"],"prefix":"10.1016","volume":"133","author":[{"given":"Alena","family":"Rand\u00e1kov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Dolej\u0161\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladim\u00edr","family":"Rudajev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Zim\u010d\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladim\u00edr","family":"Dole\u017eal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esam E.","family":"El-Fakahany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Jakub\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.01.027_bib1","series-title":"Methods Neurosci","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors","author":"Ballesteros","year":"1995"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0026-895X(25)09650-6","article-title":"Effect of the lipid environment on the differential affinity of purified cerebral and atrial muscarinic acetylcholine receptors for pirenzepine","volume":"36","author":"Berstein","year":"1989","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1172\/JCI87526","article-title":"M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss","volume":"127","author":"Bradley","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0006-8993(98)00267-4","article-title":"Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in\u00a0vivo and other cholinomimetic effects","volume":"795","author":"Bymaster","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib5","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0026-895X(24)13285-3","article-title":"On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor","volume":"53","author":"Christopoulos","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib6","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.2174\/138161205774370762","article-title":"Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease","volume":"11","author":"Clader","year":"2005","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bcp.2007.04.009","article-title":"Cholesterol as a determinant of cooperativity in the M2 muscarinic cholinergic receptor","volume":"74","author":"Colozo","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1517\/13543784.12.10.1633","article-title":"Treatment of dementia with neurotransmission modulation","volume":"12","author":"Doggrell","year":"2003","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib9","series-title":"Handb Exp Pharmacol","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-23274-9_1","article-title":"Overview of muscarinic receptor subtypes","author":"Eglen","year":"2012"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib10","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bpj.2014.10.011","article-title":"Two classes of cholesterol binding sites for the \u03b22AR revealed by thermostability and NMR","volume":"107","author":"Gater","year":"2014","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chemphyslip.2016.04.006","article-title":"Interaction of G protein coupled receptors and cholesterol","volume":"199","author":"Gimpl","year":"2016","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.105.090134","article-title":"Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor","volume":"315","author":"Grant","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbamem.2013.07.018","article-title":"Interaction of membrane\/lipid rafts with the cytoskeleton: impact on signaling and function: membrane\/lipid rafts, mediators of cytoskeletal arrangement and cell signaling","volume":"1838","author":"Head","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1124\/jpet.301.3.1033","article-title":"Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor","volume":"301","author":"Jakub\u00edk","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib15","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.33549\/physiolres.931449","article-title":"Importance and prospects for design of selective muscarinic agonists","volume":"57","author":"Jakub\u00edk","year":"2008","journal-title":"Physiol. Res."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00894-015-2824-9","article-title":"Towards predictive docking at aminergic G-protein coupled receptors","volume":"21","author":"Jakub\u00edk","year":"2015","journal-title":"J.\u00a0Mol. Model."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tips.2010.05.004","article-title":"Signaling pathways in schizophrenia: emerging targets and therapeutic strategies","volume":"31","author":"Karam","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/prot.20251","article-title":"Making optimal use of empirical energy functions: force-field parameterization in crystal space","volume":"57","author":"Krieger","year":"2004","journal-title":"Proteins"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12735","article-title":"Activation and allosteric modulation of a muscarinic acetylcholine receptor","volume":"504","author":"Kruse","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib20","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.bbamem.2010.09.019","article-title":"Adenosine receptors and membrane microdomains","volume":"1808","author":"Lasley","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib21","doi-asserted-by":"crossref","first-page":"22108","DOI":"10.1074\/jbc.M109.030411","article-title":"Differential effect of membrane cholesterol removal on \u03bc- and \u03b4-opioid receptors. A parallel comparison of acute and chronic signaling to adenylyl cyclase","volume":"284","author":"Levitt","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib22","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1124\/mol.114.096925","article-title":"The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor","volume":"87","author":"Liste","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1126\/science.1219218","article-title":"Structural basis for allosteric regulation of GPCRs by sodium ions","volume":"337","author":"Liu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib25","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1074\/jbc.274.11.7309","article-title":"The functional topography of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis","volume":"274","author":"Lu","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the \u03bc-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.18432","article-title":"Mechanism of allosteric regulation of \u03b22-adrenergic receptor by cholesterol","volume":"5","author":"Manna","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib28","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.pain.2011.09.017","article-title":"The M1\/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action","volume":"152","author":"Martino","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib29","doi-asserted-by":"crossref","first-page":"28584","DOI":"10.1074\/jbc.M111.259788","article-title":"Structural basis of M3 muscarinic receptor dimer\/oligomer formation","volume":"286","author":"McMillin","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib30","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1073\/pnas.1309755110","article-title":"Activation and dynamic network of the M2 muscarinic receptor","volume":"110","author":"Miao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2009.01.028","article-title":"Membrane cholesterol content influences binding properties of muscarinic M2 receptors and differentially impacts activation of second messenger pathways","volume":"606","author":"Michal","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib32","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1007\/s11064-014-1325-z","article-title":"Changes in membrane cholesterol differentially influence preferential and non-preferential signaling of the M1 and M3 muscarinic acetylcholine receptors","volume":"40","author":"Michal","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1124\/mol.113.084780","article-title":"The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization","volume":"84","author":"Milligan","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.sbi.2011.09.007","article-title":"Uncovering the intimate relationship between lipids, cholesterol and GPCR activation","volume":"21","author":"Oates","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib35","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1074\/jbc.M115.712562","article-title":"Dynamic regulation of quaternary organization of the M1 muscarinic receptor by subtype-selective antagonist drugs","volume":"291","author":"Pediani","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib36","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nn0403-345","article-title":"Alzheimer's disease: the cholesterol connection","volume":"6","author":"Puglielli","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2015.04.002","article-title":"Classical and atypical agonists activate M1 muscarinic acetylcholine receptors through common mechanisms","volume":"97","author":"Rand\u00e1kov\u00e1","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib39","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1021\/ja5055109","article-title":"Position of transmembrane helix 6 determines receptor G protein coupling specificity","volume":"136","author":"Rose","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088910","article-title":"Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors","volume":"9","author":"\u0160antr\u016f\u010dkov\u00e1","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature17188","article-title":"Crystal structures of the M1 and M4 muscarinic acetylcholine receptors","volume":"531","author":"Thal","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.01.027_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.027_bib45","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/bioinformatics\/btr254","article-title":"A\u00a0graphical interface for the FoldX forcefield","volume":"27","author":"Van Durme","year":"2011","journal-title":"Bioinformatics"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T20:46:04Z","timestamp":1751489164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818300273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":45,"alternative-id":["S0028390818300273"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.027","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of membrane cholesterol in differential sensitivity of muscarinic receptor subtypes to persistently bound xanomeline","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}